Prof. Dr. med. Peter Fasching



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Germline variants of homology-directed repair or mismatch repair genes in cervical cancer () Kokemüller L, Ramachandran D, Schürmann P, Geffers R, Jentschke M, Böhmer G, Strauß HG, et al. Journal article Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer (2025) Hoppe R, Winter S, Lo WY, Michailidou K, Bolla MK, Keeman R, Wang Q, et al. Journal article Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis (2025) Fu Z, Borho L, Taylor SE, Kelemen LE, DeFazio A, Webb PM, Köbel M, et al. Journal article Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study (2025) Decker T, Brucker C, Engel A, Fasching P, Göhler T, Jackisch C, Janssen J, et al. Journal article Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk (2025) Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching P, Harbeck N, et al. Journal article Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer Update Mammakarzinom 2024 Teil 3 – Patientinnen mit fortgeschrittenen Stadien des Mammakarzinoms (2025) Lüftner D, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Journal article, Review article Update Breast Cancer 2024 Part 2-Patients with Early Stage Breast Cancer Update Mammakarzinom 2024 Teil 2 – Patientinnen mit Frühstadien des Mammakarzinoms (2025) Janni W, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Journal article, Review article Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study (2025) Fasching P, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, Link T, et al. Journal article Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes (2025) Collin LJ, Cushing-Haugen KL, Terry KL, Goode EL, Wu AH, Harris HR, Sasamoto N, et al. Journal article Fully automatic HER2 tissue segmentation for interpretable HER2 scoring (2025) Öttl M, Steenpaß J, Wilm F, Qiu J, Rübner M, Lang-Schwarz C, Taverna C, et al. Journal article